Press Releases HBM Holdings Limited

Equities

2142

KYG4403H1002

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
1.38 ^HKD	+0.73%		-5.48%	-28.87%

May. 23	Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	MT
May. 23	HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies	May. 22	PR
Harbour BioMed Reports Full Year 2023 Financial Results	Mar. 28	PR
Harbour BioMed Announces Positive Profit Alert	Jan. 18	PR
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	Dec. 15	AQ
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	23-08-08	PR
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation	23-07-13	PR
Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics	23-05-24	AQ
Harbour BioMed Reports Full Year 2022 Financial Results	23-04-03	PR
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics	23-02-13	AQ
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders	23-01-25	PR
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics	22-11-21	AQ
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna	22-11-10	PR
MISSISSIPPI LIME COMPANY DRIVES GLOBAL EXPANSION WITH THE ACQUISITION OF SINGLETON BIRCH	22-09-08	AQ
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board	22-05-05	PR
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022	22-04-06	PR
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities	22-03-24	PR
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003	22-01-04	PR
Harbour BioMed : Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003	21-09-14	PR
HBM : VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE Ib/IIa CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA	21-05-12	PU
HBM : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING	21-04-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases HBM Holdings Limited

Equities

2142

KYG4403H1002

Press Releases

Filters